Hyperbaric Oxygen Therapy Ameliorates Olanzapine-Induced Hypolocomotion in a Rat Model

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Nov 27

PMID 39598279

Authors

Ahmad Altarifi

Linah Arab

Rasha Al-Azaizeh

Batool Khataybeh

Muath Q Al-Ghadi

Mohammad Khalifeh

Affiliations

Soon will be listed here.

Abstract

Olanzapine (OLZ) is a commonly prescribed drug for the treatment of schizophrenia and related disorders. However, OLZ use is associated with several adverse effects, including decreased locomotor activity and increased body weight. While the majority of studies have directed their focus towards managing the metabolic side effects of OLZ, there has been limited attention given to the effects on locomotor activity. This study aimed to investigate the potential therapeutic effect of hyperbaric oxygen therapy (HBOT) in alleviating OLZ-induced locomotor impairment in female Sprague Dawley rats. Subjects were divided into four groups: control rats (CR), HBOT, OLZ, and HBOT + OLZ. In addition to behavioral effects, we also evaluated the total antioxidant capacity (TAC) of rats' brain tissue to demonstrate the maintenance of OLZ effectiveness in improving antioxidant status during the intervention using a rotarod device to measure locomotor activity and coordination. Results showed that HBOT effectively counteracted the hypolocomotion produced after OLZ administration. Moreover, HBOT did not result in a decrease in TAC in brain tissue, which is linked to OLZ treatment effectiveness. Therefore, our results suggest that HBOT may represent a promising non-pharmacological approach to improving locomotor and motor coordination impairments associated with OLZ treatment.

References

Sureda A, Batle J, Martorell M, Capo X, Tejada S, Tur J . Antioxidant Response of Chronic Wounds to Hyperbaric Oxygen Therapy. PLoS One. 2016; 11(9):e0163371. PMC: 5031445. DOI: 10.1371/journal.pone.0163371. View

Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva V . Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017; 13:2231-2241. PMC: 5574691. DOI: 10.2147/NDT.S113099. View

Miller D . Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2005; 6(Suppl 2):3-7. PMC: 487011. View

Pu C, Huang B, Zhou T, Cheng Z, Wang Y, Shi C . Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia. Neuropsychiatr Dis Treat. 2020; 16:3145-3152. PMC: 7751687. DOI: 10.2147/NDT.S280719. View

Ye Y, Lin H, Wan M, Qiu P, Xia R, He J . The Effects of Aerobic Exercise on Oxidative Stress in Older Adults: A Systematic Review and Meta-Analysis. Front Physiol. 2021; 12:701151. PMC: 8523805. DOI: 10.3389/fphys.2021.701151. View

Gardner D, Baldessarini R, Waraich P . Modern antipsychotic drugs: a critical overview. CMAJ. 2005; 172(13):1703-11. PMC: 1150265. DOI: 10.1503/cmaj.1041064. View

Smith P, Merwin R . The Role of Exercise in Management of Mental Health Disorders: An Integrative Review. Annu Rev Med. 2020; 72:45-62. PMC: 8020774. DOI: 10.1146/annurev-med-060619-022943. View

de Wolde S, Hulskes R, Weenink R, Hollmann M, van Hulst R . The Effects of Hyperbaric Oxygenation on Oxidative Stress, Inflammation and Angiogenesis. Biomolecules. 2021; 11(8). PMC: 8394403. DOI: 10.3390/biom11081210. View

Yung L, Laher I, Yao X, Chen Z, Huang Y, Leung F . Exercise, vascular wall and cardiovascular diseases: an update (part 2). Sports Med. 2008; 39(1):45-63. DOI: 10.2165/00007256-200939010-00004. View

10.

Ahmadi F, Khalatbary A . A review on the neuroprotective effects of hyperbaric oxygen therapy. Med Gas Res. 2021; 11(2):72-82. PMC: 8130666. DOI: 10.4103/2045-9912.311498. View

11.

Chaves K, Serrano-Blanco A, Ribeiro S, Lira Soares L, Guerra G, Alves M . Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatr Q. 2012; 84(1):125-35. DOI: 10.1007/s11126-012-9233-3. View

12.

Caruso G, Grasso M, Fidilio A, Tascedda F, Drago F, Caraci F . Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia. Pharmaceuticals (Basel). 2020; 13(12). PMC: 7764768. DOI: 10.3390/ph13120457. View

13.

Mittal V, Vargas T, Osborne K, Dean D, Gupta T, Ristanovic I . Exercise Treatments for Psychosis: A Review. Curr Treat Options Psychiatry. 2017; 4(2):152-166. PMC: 5636011. DOI: 10.1007/s40501-017-0112-2. View

14.

Silvestrini A, Meucci E, Ricerca B, Mancini A . Total Antioxidant Capacity: Biochemical Aspects and Clinical Significance. Int J Mol Sci. 2023; 24(13). PMC: 10341416. DOI: 10.3390/ijms241310978. View

15.

Salim S . Oxidative Stress and the Central Nervous System. J Pharmacol Exp Ther. 2016; 360(1):201-205. PMC: 5193071. DOI: 10.1124/jpet.116.237503. View

16.

Jang Y, Hur H, Park B, Park H . Psychosocial Factors Associated with dizziness and chronic dizziness: a nationwide cross-sectional study. BMC Psychiatry. 2024; 24(1):13. PMC: 10762808. DOI: 10.1186/s12888-023-05464-7. View

17.

Tibbles P, Edelsberg J . Hyperbaric-oxygen therapy. N Engl J Med. 1996; 334(25):1642-8. DOI: 10.1056/NEJM199606203342506. View

18.

Seeman M . Men and women respond differently to antipsychotic drugs. Neuropharmacology. 2019; 163:107631. DOI: 10.1016/j.neuropharm.2019.05.008. View

19.

Brinholi F, de Farias C, Bonifacio K, Higachi L, Casagrande R, Moreira E . Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models. Biomed Pharmacother. 2016; 81:411-415. DOI: 10.1016/j.biopha.2016.02.047. View

20.

Kirschbaum K, Hiemke C, Schmitt U . Rotarod impairment: catalepsy-like screening test for antipsychotic side effects. Int J Neurosci. 2009; 119(10):1509-22. DOI: 10.1080/00207450902984002. View